Faiyaz Rahman

Mr. Faiyaz Rahman

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
FRFaiyaz Rahman
Faiyaz Rahman
RNRoshan Nanu
Roshan Nanu
NSNathan A. Schneider
Nathan A. Schneider
DKDonald Katz
Donald Katz
JLJohn Lisman
John Lisman
HPHyun-Jae Pi
Hyun-Jae Pi

31 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AKAndrew James Kinloch
Andrew James Kinloch
FRFaiyaz Rahman
Faiyaz Rahman
BKBahriye Karakas
Bahriye Karakas
MSMuhammad Shahid
Muhammad Shahid
BLBora Lim
Bora Lim
Michael CardoneMichael Cardone
Michael Cardone
One of the hallmarks of cancer cells is their failure to respond to the cellular mechanism of apoptosis. The B-cell lymphoma 2 (BCL-2) family of proteins regulate apoptosis. Their ability to do so can be measured using several methods that in turn anticipate the fate of the cancer cell in response to apoptosis-inducing treatment. These assays ultimately identify the readiness of the cancer cell to undergo apoptosis, which is referred to as the mitochondrial priming state. These metrics, however, have been challenging to implement in the clinic. Methods: Here, we describe a unique method that relies on a panel of novel conformation-specific antibodies (termed PRIMAB) that can directly measure the mitochondrial priming state. These reagents are highly specific for complexes of their corresponding pro-survival protein interactions with the pro-apoptotic protein BIM. These BIM-containing heterodimeric complexes have long been established as hallmarks of primed cancer cells. Results: Using clinically amenable assay formats, PRIMABs were shown to detect the presence of these anti-apoptotic–pro-apoptotic complexes and their disruption by BH3-mimetic drugs. Moreover, PRIMABs were able to detect a shift in priming status following BH3-mimetic treatment, a factor associated with resistance to these drugs. In a panel of AML patient samples, we report a wide range of priming levels for each PRIMAB complex, demonstrating the potential for heterogeneity in responses. We also show that PRIMABs could be predictive of outcomes for AML patients following cytarabine-based treatment. Conclusions: PRIMABs provide novel and useful tools for cancer research and for clinical implementation as reagents providing predictive tests for treatment response.